These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4186018)

  • 1. Fasting serum triglyceride, cholesterol, and lipoprotein levels during oral-contraceptive therapy.
    Wynn V; Mills GL; Doar JW; Stokes T
    Lancet; 1969 Oct; 2(7624):756-60. PubMed ID: 4186018
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipid and lipoprotein levels in a Danish population.
    Dyerberg J; Hjorne N
    Acta Med Scand; 1972 May; 191(5):413-21. PubMed ID: 4337998
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid metabolism in pregnancy. I. Changes in lipoprotein triglyceride and cholesterol in normal pregnancy and the effects of diabetes mellitus.
    Knopp RH; Warth MR; Carrol CJ
    J Reprod Med; 1973 Mar; 10(3):95-101. PubMed ID: 4348501
    [No Abstract]   [Full Text] [Related]  

  • 5. Progestagens, anabolic-androgenic compounds, estrogens: effects on triglycerides and postheparin lipolytic enzymes.
    Glueck CJ; Scheel D; Fishback J; Steiner P
    Lipids; 1972 Feb; 7(2):110-3. PubMed ID: 4551949
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma lipid and lipoprotein alterations during oral contraceptive administration.
    Sachs BA; Wolfman L; Herzig N
    Obstet Gynecol; 1969 Oct; 34(4):530-5. PubMed ID: 5822679
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasting serum lipids and serum lipoprotein distribution during oral contraceptive therapy in Nigerians.
    Kuku SB; Akinyanju PA
    J Obstet Gynaecol Br Commonw; 1973 Aug; 80(8):750-3. PubMed ID: 4725954
    [No Abstract]   [Full Text] [Related]  

  • 9. [The metabolic effects of contraception with oestrogen-progestogen products (author's transl)].
    Heim J
    J Gynecol Obstet Biol Reprod (Paris); 1979; 8(8):745-9. PubMed ID: 233376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum apolipoprotein A-I levels: relationship to lipoprotein lipid levels and selected demographic variables.
    Phillips NR; Havel RJ; Kane JP
    Am J Epidemiol; 1982 Aug; 116(2):302-13. PubMed ID: 6810694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood lipids and lipoproteins in a Minnesota urban population.
    Jacobs DR; Hunninghake DB; Dempsey ME; Taylor HL; Kuba K; Luepker RV; Dawson EA; Frantz ID; Hannan P
    J Chronic Dis; 1980; 33(7):395-406. PubMed ID: 7380974
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of a progestin, quingestanol, in older diabetic women.
    Danowski TS; Wilson HR; Khurana RC; Jung Y; Gonzalez AR; Sunder JH
    Horm Res; 1973; 4(2):84-96. PubMed ID: 4748469
    [No Abstract]   [Full Text] [Related]  

  • 13. Some effects of oral contraceptives on carbohydrate metabolism.
    Wynn V; Doar JW
    Lancet; 1969 Oct; 2(7624):761-5. PubMed ID: 4186019
    [No Abstract]   [Full Text] [Related]  

  • 14. [Estrogens, progestins and blood lipids].
    Tikkanen MJ
    Duodecim; 1984; 100(22):1500-3. PubMed ID: 6518995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The heritability of serum lipoprotein and lipid concentrations. A twin study.
    Heiberg A
    Clin Genet; 1974; 6(4):307-16. PubMed ID: 4474930
    [No Abstract]   [Full Text] [Related]  

  • 16. Altered plasma lipid and lipoprotein levels associated with oral contraceptive and oestrogen use. Report from the Medications Working Group of the Lipid Research Clinics Program.
    Wallace RB; Hoover J; Barrett-Connor E; Rifkind BM; Hunninghake DB; Mackenthun A; Heiss G
    Lancet; 1979 Jul; 2(8134):112-5. PubMed ID: 88553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum insulin and intravenous glucose tolerance in oral contraception.
    Starup J; Date J; Deckert T
    Acta Endocrinol (Copenh); 1968 Jul; 58(3):537-44. PubMed ID: 4872295
    [No Abstract]   [Full Text] [Related]  

  • 18. [Metabolism of circulating lipids in patients taking oral contraceptives].
    Turpin G; Menage JJ
    Sem Hop; 1973 Oct; 49(43):2833-8. PubMed ID: 4362577
    [No Abstract]   [Full Text] [Related]  

  • 19. [Influence of ovulation inhibitors on glucose metabolism].
    Hausmann L; Kaffarnik H
    Dtsch Med Wochenschr; 1975 Aug; 100(34):1703-9. PubMed ID: 1098884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma lipid and lipoprotein changes during "pill-a-month" contraceptive steroid administration.
    Sachs BA; Wolfman L
    Am J Obstet Gynecol; 1971 Jan; 109(1):155-8. PubMed ID: 4923383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.